Behavioral and Pharmacologic Treatment of Aggression in Children With Autism
|
|
- Maximilian Fletcher
- 8 years ago
- Views:
Transcription
1 Behavioral and Pharmacologic Treatment of Aggression in Children With Autism By Craig A. Erickson, M.D., Naomi B. Swiezy, Ph.D., Kimberly A. Stigler, M.D., Christopher J. McDougle, M.D., and David J. Posey, M.D., Psychiatric Times URL: Psychiatric Times September 2005 Vol. XXII Issue 10 Autistic disorder (autism) is a childhood-onset disorder characterized by marked impairments in social interaction, communication and behavior. Aggression is a frequent reason for psychiatric referral in this population. As such, the clinician needs to be knowledgeable regarding aggression assessment and treatment. This article will provide an overview of treatment modalities, with emphasis on the future direction of interventions targeting aggression in children with autism. Assessment Behavioral and pharmacologic interventions cannot begin until the patient has been thoroughly assessed in terms of diagnosis, cognitive abilities and other factors related to the complaint of aggression. In identifying these factors, it is important to begin with a detailed inquiry as to the duration, frequency and severity of the aggression, as well as precipitating or exacerbating factors. Evaluation for comorbid psychiatric disorders (e.g., major depression) and symptoms (e.g., impulsivity), as well as medical conditions (e.g., epilepsy), is also important in guiding interventions. An initial behavioral assessment, called a functional analysis, is performed prior to behavioral therapy. Functional analyses are controlled observational sessions that are conducted to objectively determine the primary motivating factor for the child's misbehavior. Primary motivational factors or functions of behavior are typically to seek attention, access a preferred item or escape a task. Another function may be that the child engages in a behavior that is inherently pleasurable. As such, determination of any appropriate and beneficial treatment approach would be selected on the basis of the empirically determined motivational factor, rather than on arbitrary selection (Hagopian et al., 2001). Behavioral Interventions Behavioral interventions, particularly those based upon applied behavior analysis (ABA), have long had empirical support for addressing problematic behavior (for a review, see Schreibman, 2000). These methods have been utilized for a wide range of disorders and myriad behavioral difficulties (Heflin and Simpson, 1998) and have not been exclusively utilized for the treatment of autism. However, intervention with roots in ABA has been regarded as one of the primary forms of treatment, given its stability in the literature and practice over decades, as well as the fact that it lends itself to objective evaluation. In general, ABA refers to methodologies based in operant conditioning theory and presumes that antecedent stimuli and consequences influence acquisition and continuation of behaviors. Objective assessment of observable and measurable behaviors and ongoing evaluation of the behavior change is inherent in treatment success. Particularly in the field of autism, terminology has often become muddled over the years. Many particular methodologies are equated to the whole of ABA, as opposed to being one tool or method within this rubric.
2 Specific methodologies enveloped within the field of ABA include Lovaas therapy or discrete trial teaching (Lovaas, 1987) and incidental teaching (McGee et al., 1999). Although based on the principles of ABA, these specific methodologies should be viewed as distinct interventions within the general framework of ABA. Several behavioral strategies have been shown to be effective in decreasing severe aggression and self-injury (Kahng et al., 2001). Since intervention methods are best employed on a consistent and daily basis, parental involvement is very important (Briesmeister and Schaefer, 1998). In fact, parents and other caregivers are often a primary focus of training in ABA methods. There are many challenges in providing this training, as well as ensuring consistent implementation of treatment intervention, particularly for behaviors such as aggression. Follow-up visits to coach the caregivers and ensure protocol fidelity are often infrequent. In addition, caregivers working in naturalistic settings with these children face inherent multiple challenges and competing time pressures on a daily basis. Providing prevention techniques that will prevent or limit the development of maladaptive behavior is more realistic in these settings (McClannahan and Krantz, 2004). In addition, there has been documented success of parent and staff training interventions based in ABA to improve the caregiver's abilities to provide all levels of prevention, treatment intervention and skills acquisition. In particular, Harris et al. (in press) have completed a comprehensive review of the methods and strategies considered most useful for consistent and effective treatment implementation. Included are instructions, modeling/role-playing and corrective feedback, as well as ongoing consultation. While much single-case research supports ABA intervention, randomized control trials have not thoroughly evaluated the efficacy of a standardized behavioral intervention program. The difficulty in doing so is inherent in the particular strength of behavioral analytic techniques to individualize the treatment to the characteristics and interests of the particular child. The National Institute of Mental Health recently funded three Research Units on Pediatric Psychopharmacology (RUPP) that are focused on autism and related pervasive developmental disorders (PDDs). The RUPP Autism Network has begun a controlled investigation into the use of a standardized behavioral intervention, targeting severe behaviors such as aggression and self-injury. Although the behavioral programming is not specific to the principles of ABA and will not prove the particular success of such an intervention with this population, the investigation will provide some input as to the benefit of incorporating general behavioral methods along with psychopharmacological intervention. Furthermore, it will provide a basis for manualizing a behavioral intervention so therapists without extensive experience with children with autism will have some guide to appropriate intervention strategies. Pharmacotherapy Several drug classes, including antipsychotics, serotonin reuptake inhibitors, mood stabilizers, psychostimulants and adrenergic agonists, have been evaluated in studies where aggression was a primary target in children with autism. Antipsychotics. Typical antipsychotics were among the first agents assessed in an organized manner. Haloperidol (Haldol) decreased emotional outbursts and anger in placebo-controlled studies including young children with autism (Anderson et al., 1984). However, its role is limited due to concerns about dystonic reactions and dyskinesias (Campbell et al., 1997). Atypical antipsychotic drugs have a reduced propensity to cause motor side effects and have largely replaced haloperidol in the clinical treatment of autism. Clozapine (Clozaril), quetiapine (Seroquel), olanzapine (Zyprexa) and ziprasidone (Geodon) have been evaluated in small or uncontrolled studies and case reports (Erickson et al., in press). Each of these drugs, with the exception of ziprasidone, is associated with frequent weight gain. Clozapine
3 has additional liabilities, given its propensity to decrease the seizure threshold and requirement for frequent venipuncture. Among the atypical antipsychotics, risperidone (Risperdal) has received the most attention in treating maladaptive behaviors in patients with autism. This drug has been the subject of controlled trials in both adults (McDougle et al., 1998) and children (McCracken et al., 2002; Shea et al., 2004). McCracken et al. (2002) compared risperidone (mean dose=1.8 mg/day) to placebo in an eight-week, randomized, double-blind trial in 101 children with autism. Risperidone was markedly efficacious in reducing aggression and irritability. Side effects included weight gain, increased appetite, sedation, tremor and hypersalivation. Shea and colleagues (2004) also reported that risperidone (mean dose=0.04 mg/kg/day) was efficacious in reducing irritability, conduct problems, anxiety and hyperactivity in an eightweek, double-blind, placebo-controlled study of risperidone in a sample of 79 children. They also found significant weight gain, as well as increased pulse and systolic blood pressure in the risperidone-treated group. Our group recently reported that aripiprazole (Abilify) (mean dose=12 mg/day) was effective for reducing aggression, agitation and self-injury in five youth with PDD (Stigler et al., 2004). During open-label aripiprazole treatment (mean duration=12 weeks), two patients experienced mild somnolence, but no changes in vital signs occurred. Weight loss was also noted. This weight loss may have been associated with patients discontinuing other medications that had caused excess weight gain. We are currently conducting a large placebo-controlled trial of aripiprazole for children and adolescents with autism and aggression. Other psychotropic agents. Clonidine (Catapres), an α2-adrenergic agonist, was efficacious in two short-term, placebo-controlled trials, but its long-term efficacy has been questioned (McDougle et al., 2003). Guanfacine, a longer-acting α2-adrenergic agonist, was only effective in 19 of 80 (24%) patients with PDD at mean treatment duration of one year (Posey et al., 2004b). Out of 69 patients with significant aggression, it was only effective in 10 (14%) patients. Case reports and a retrospective review have reported on the use of lithium (Eskalith, Lithobid) or divalproex (Depakote) for aggressive behaviors in youth with autism (McDougle et al., 2003). While we expect more reports on the use of mood stabilizers in the future, our clinical experience, combined with available evidence, suggests that mood stabilizers will not be as effective as atypical antipsychotics in treating aggression. The tricyclic antidepressant clomipramine (Anafranil) has shown some promise in treating aggression in one placebo-controlled trial (Gordon et al., 1993). Secondary to concerns over tolerability and the availability of safer selective serotonin reuptake inhibitors, the use of clomipramine has been limited. Fluvoxamine (Luvox) (mean dose=277 mg/day) was evaluated in a 12-week, randomized, placebo-controlled trial in 30 adults with autism (McDougle et al., 1996). Fluvoxamine was associated with significant global symptom improvement, as well as a reduction in maladaptive behavior and aggression. The same group conducted a similar study in 34 children with PDD but noted increased aggression without overall improvement (McDougle et al., unpublished data). Hollander and colleagues (2005) reported on an eight-week, double-blind, placebo-controlled crossover trial of liquid fluoxetine (Prozac) in 45 children and adolescents with PDD. There was a reduction in repetitive behaviors but less reduction of global symptoms. Overall, SSRIs as first-line agents in targeting aggressive behaviors in children with autism is not currently supported by the available literature. While psychostimulant treatment has been associated with reductions in aggression in children with attention-deficit/hyperactivity disorder, results in autism have been equivocal. Posey et al. (2004a) reported on a randomized, placebo-controlled, crossover study of methylphenidate (Ritalin, Concerta, Metadate) in children with PDD. Methylphenidate
4 treatment was associated with small-to-medium improvements in hyperactivity but caused irritability in some patients. There was no improvement in aggression. Conclusion A comprehensive treatment plan for treating aggressive behaviors in children with autism begins with a precise and thorough assessment, followed by implementation of a comprehensive treatment plan. This treatment plan must incorporate ongoing behavioral assessment and intervention with continuous evaluation for areas in which pharmacotherapy could potentially curtail maladaptive and dangerous behaviors. From a pharmacotherapy perspective, atypical antipsychotics, particularly risperidone, have shown the most promise in reducing aggressive behavior. Future directions in treating aggression in children with autism include further investigation of atypical antipsychotics that may not cause significant weight gain and testing the efficacy of manualized behavioral treatments. Dr. Erickson is a resident in psychiatry at the Indiana University School of Medicine and the Christian Sarkine Autism Treatment Center (CSATC). Dr. Swiezy is clinical associate professor of psychology and psychiatry at the Indiana University School of Medicine and clinical director of CSATC. Dr. Stigler is assistant professor of psychiatry at the Indiana University School of Medicine. Dr. McDougle is the Albert E. Sterne Professor and chairperson of the department of psychiatry at the Indiana University School of Medicine. Dr. Posey is associate professor of psychiatry at the Indiana University School of Medicine and chief of CSATC. References Anderson LT, Campbell M, Grego DM (1984), Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141(10): Briesmeister JM, Schaefer CE (1998), Handbook of Parent Training: Parents as Co- Therapists for Children's Behavioral Problems. New York: Wiley. Campbell M, Armenteros JL, Malone RP et al. (1997), Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36(6): Erickson CA, Stigler KA, Posey DJ et al. (in press), Psychopharmacology. In: Autism and Pervasive Developmental Disorders, Volkmar F, ed. New York: Cambridge University Press. Gordon CT, State RC, Nelson JF et al. (1993), A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50(6): Hagopian LP, Wilson DM, Wilder DA (2001), Assessment and treatment of problem behavior maintained by escape from attention and access to tangible items. J Appl Behav Anal 34(2): Harris SL, LaRue R, Weiss MJ (in press), Programmatic issues. In: Autism Spectrum Disorders: Applied Behavior Analysis, Evidence and Practice, Sturmey P, Fitzer A, eds. Austin, Texas: PRO-ED. Heflin LJ, Simpson RL (1998), Interventions for children and youth with autism: prudent choices in a world of exaggerated claims and empty promises. Part I: intervention and treatment option review. Focus on Autism and Other Developmental Disabilities 13: Hollander E, Phillips A, Chaplin W et al. (2005), A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism.
5 Neuropsychopharmacology 30(3): Kahng S, Abt KA, Schonbachler HE (2001), Assessment and treatment of low-rate highintensity problem behavior. J Appl Behav Anal 34(2): Lovaas OI (1987), Behavioral treatment and normal educational and intellectual functioning in young autistic children. J Consult Clin Psychol 55(1):3-9 [see comment]. McClannahan LE, Krantz PJ (2004), Some guidelines for selecting behavioral intervention programs for children with autism. In: Using Evidence in Social Work Practice: Behavioral Perspectives, Briggs HE, Rzepnicki TL, eds. Chicago: Lyceum Books. McCracken JT, McGough J, Shah B et al. (2002), Risperidone in children with autism and serious behavioral problems. N Engl J Med 347(5): [see comments]. McDougle CJ, Holmes JP, Carlson DC et al. (1998), A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55(7): [see comment]. McDougle CJ, Naylor ST, Cohen DJ et al. (1996), A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53(11): [see comments]. McDougle CJ, Stigler KA, Posey DJ (2003), Treatment of aggression in children and adolescents with autism and conduct disorder. J Clin Psychiatry 64(suppl 4): McGee GG, Morrier MJ, Daly T (1999), An incidental teaching approach to early intervention for toddlers with autism. Journal of the Association for Persons with Severe Handicaps 24(3): Posey DJ, McDougle CJ, Aman MG et al. (2004a), A randomized, double-blind, placebocontrolled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders. Neuropsychopharmacology 29(suppl 1):S142. Posey DJ, Puntney JI, Sasher TM et al. (2004b), Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14(2): Schreibman L (2000), Intensive behavioral/psychoeducational treatments for autism: research needs and future directions. J Autism Dev Disord 30(5): Shea S, Turgay A, Carroll A et al. (2004), Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114(5): Stigler KA, Posey DJ, McDougle CJ (2004), Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14(3): Copyright 2006 CMP Healthcare Media Group LLC, a United Business Media company Privacy Statement Terms of Service
Comorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014
Comorbid Conditions in Autism Spectrum Illness David Ermer MD June 13, 2014 Overview Diagnosing comorbidities in autism spectrum illnesses Treatment issues specific to autism spectrum illnesses Treatment
More informationMedications Used in the Management of Disruptive Behavior Disorders
The following medication chart is provided as a brief guide to some of the medications used in the management of various behavior disorders, along with their potential benefits and possible side effects.
More informationBipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:
Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic
More informationPsychopharmacotherapy for Children and Adolescents
TREATMENT GUIDELINES Psychopharmacotherapy for Children and Adolescents Guideline 7 Psychopharmacotherapy for Children and Adolescents Description There are few controlled trials to guide practitioners
More informationTherapies for Children With Autism Spectrum Disorders. A Review of the Research for Parents and Caregivers
Therapies for Children With Autism Spectrum Disorders A Review of the Research for Parents and Caregivers Is This Guide Right for the Child in My Care? Yes, if: The child you care for is between 2 and
More informationPSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that
More informationOverview of Mental Health Medication Trends
America s State of Mind Report is a Medco Health Solutions, Inc. analysis examining trends in the utilization of mental health related medications among the insured population. The research reviewed prescription
More informationMEDICATIONS AND TOURETTE S DISORDER: COMBINED PHARMACOTHERAPY AND DRUG INTERACTIONS. Barbara Coffey, M.D., Cheston Berlin, M.D., Alan Naarden, M.D.
MEDICATIONS AND TOURETTE S DISORDER: COMBINED PHARMACOTHERAPY AND DRUG INTERACTIONS Barbara Coffey, M.D., Cheston Berlin, M.D., Alan Naarden, M.D. Introduction Tourette Syndrome (TS) or Tourette s Disorder
More informationADHD PRACTISE PARAMETER. IRSHAAD SHAFFEEULLAH, M.D. A diplomate American Board of CHILD AND ADOLESCENT PSYCHIATRY
ADHD PRACTISE PARAMETER IRSHAAD SHAFFEEULLAH, M.D. A diplomate American Board of CHILD AND ADOLESCENT PSYCHIATRY Similar type of idea Similar document Similar document AACAP document Neurobiological condition
More informationNew Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine
New Treatments For Bipolar Disorder Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine Abbott Laboratories AstraZeneca Bristol-Myers Squibb Corcept
More informationAutism Spectrum Disorders and Comorbid Behavioral Health Symptoms
Autism Spectrum Disorders and Comorbid Behavioral Health Symptoms Cynthia King, MD Child and Adolescent Psychiatrist Associate Professor of Psychiatry UNMSOM Psychopharmacologic and Alternative Medicine
More informationPsychiatric Medications: Pearls and Pitfalls. The majority of medications used in patients with psychiatric diagnoses have more than one use.
Psychiatric Medications: Pearls and Pitfalls Rule #1 The majority of medications used in patients with psychiatric diagnoses have more than one use. Without access to the patient s medical record, to review
More informationThe Pharmacological Management of Depression in the Adult Person with Mental Retardation and Developmental Disabilities (MR/DD)
The Pharmacological Management of Depression in the Adult Person with Mental Retardation and (MR/DD) 1. Overview Multiple classes of medications are available for treatment of depression in the patient
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
More informationMEDICAL POLICY SUBJECT: APPLIED BEHAVIOR ANALYSIS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS
MEDICAL POLICY SUBJECT: APPLIED BEHAVIOR ANALYSIS FOR PAGE: 1 OF: 7 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product covers
More informationChildhood Rage: Diagnosis and Treatment Strategies for Severe Mood Dysregulation - Part 2: Diagnosis and Treatment
Liberty University DigitalCommons@Liberty University Faculty Publications and Presentations Center for Counseling and Family Studies 2013 Childhood Rage: Diagnosis and Treatment Strategies for Severe Mood
More informationEmergency Room Treatment of Psychosis
OVERVIEW The term Lewy body dementias (LBD) represents two clinical entities dementia with Lewy bodies (DLB) and Parkinson s disease dementia (PDD). While the temporal sequence of symptoms is different
More informationAutisme Spectrum Disorder & AHDH Mutually Exclusive?!? a Clinical Issue
Autisme Spectrum Disorder & AHDH Mutually Exclusive?!? a Clinical Issue Rutger Jan van der Gaag MD PhD UMC St. Radboud / Karakter UCN University Department Child & Adolescent Psychiatry Nijmegen, the Netherlands
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationAutism Spectrum Disorders and Co-Occurring Mental Health Conditions
Autism Spectrum Disorders and Co-Occurring Mental Health Conditions Sydney Rice, MD, MS University of Arizona LEND Erika Ryst, M.D. University of Nevada LEND October 5, 2015 Overview Children with autism
More informationBRIEF NOTES ON THE MENTAL HEALTH OF CHILDREN AND ADOLESCENTS
BRIEF NOTES ON THE MENTAL HEALTH OF CHILDREN AND ADOLESCENTS The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems
More informationA BRIEF OVERVIEW OF PSYCHOTROPIC MEDICATION USE FOR PERSONS WITH INTELLECTUAL DISABILITIES
INTRODUCTION A BRIEF OVERVIEW OF PSYCHOTROPIC MEDICATION USE FOR PERSONS WITH INTELLECTUAL DISABILITIES Individuals with intellectual disabilities are not uncommonly prescribed psychotropic medications.
More informationThe Intersection of Applied Behavior Analysis and Behavioral Pharmacology. Tom Byrne, Ph.D., BCBA-D MCLA
The Intersection of Applied Behavior Analysis and Behavioral Pharmacology Tom Byrne, Ph.D., BCBA-D MCLA Medication change Drug use is so entrenched in our society that anyone interested in human behavior
More informationsad EFFECTIVE DATE: 10 01 2013 POLICY LAST UPDATED: 06 02 2015
Medical Coverage Policy Autism Spectrum Disorders Mandate sad EFFECTIVE DATE: 10 01 2013 POLICY LAST UPDATED: 06 02 2015 OVERVIEW Applied behavioral analysis (ABA) is the process of systematically applying
More informationDSM 5 AND DISRUPTIVE MOOD DYSREGULATION DISORDER Gail Fernandez, M.D.
DSM 5 AND DISRUPTIVE MOOD DYSREGULATION DISORDER Gail Fernandez, M.D. GOALS Learn DSM 5 criteria for DMDD Understand the theoretical background of DMDD Discuss background, pathophysiology and treatment
More informationBIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS
BIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS A publication of the Massachusetts Department of Mental Health and the Massachusetts Division of Medical
More informationPsychotic Disorder. Psychosis. Psychoses may be caused by: Examples of Hallucinations and Delusions 12/12/2012
Psychosis Psychotic Disorder Dr Lim Boon Leng Psychiatrist and Medical Director Dr BL Lim Centre For Psychological Wellness Tel: 64796456 Email: info@psywellness.com.sg Web: www.psywellness.com.sg A condition
More informationEvidence for Effectiveness of ABA as a Treatment for Autism
Evidence for Effectiveness of ABA as a Treatment for Autism Introduction This document summarizes medical and scientific evidence for effectiveness of applied behavior analysis (ABA) as a treatment for
More informationGuide to Using Psychotropic Medication to Manage Behaviour Problems among Adults with Intellectual Disability
Guide to Using Psychotropic Medication to Manage Behaviour Problems among Adults with Intellectual Disability Technical Document Shoumitro Deb, MBBS, FRCPsych, MD, Clinical Professor of Neuropsychiatry
More informationAlgorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
More informationClinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder
Clinical Practice Guidelines: Attention Deficit/Hyperactivity Disorder AACAP Official Action: OUTLINE OF PRACTICE PARAMETERS FOR THE ASSESSMENT AND TREATMENT OF CHILDREN, ADOLESCENTS, AND ADULTS WITH ADHD
More informationMedications for bipolar disorder
Medications for bipolar disorder Findings from Australian National Survey of Mental Health and Wellbeing (Mitchell et al, 2004) In 12 months, only one-third saw a mental health professional 40% received
More informationIMR ISSUES, DECISIONS AND RATIONALES The Final Determination was based on decisions for the disputed items/services set forth below:
Case Number: CM13-0018009 Date Assigned: 10/11/2013 Date of Injury: 06/11/2004 Decision Date: 01/13/2014 UR Denial Date: 08/16/2013 Priority: Standard Application Received: 08/29/2013 HOW THE IMR FINAL
More informationObsessive Compulsive Disorder: a pharmacological treatment approach
Obsessive Compulsive Disorder: a pharmacological treatment approach Professor Alasdair Vance Head, Academic Child Psychiatry Department of Paediatrics University of Melbourne Royal Children s Hospital
More informationImproving the Recognition and Treatment of Bipolar Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating
More informationin young people Management of depression in primary care Key recommendations: 1 Management
Management of depression in young people in primary care Key recommendations: 1 Management A young person with mild or moderate depression should typically be managed within primary care services A strength-based
More informationAUTISM SPECTRUM DISORDER TREATMENTS
AUTISM SPECTRUM DISORDER TREATMENTS Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage
More informationUnderstanding Antipsychotic Medications
Understanding Antipsychotic Medications NARSAD RESEARCH National Alliance for Research on Schizophrenia and Depression 60 Cutter Mill Road, Suite 404 Great Neck, NY 11021 516-829-0091 1-800-829-8289 516-487-6930
More informationInappropriate prescribing
Inappropriate prescribing Research shows that all too often, Americans are taking medications that may not work or may be inappropriate for their mental health problems. By Brendan L. Smith APA Monitor
More informationBehavioral Health Diagnoses, Symptoms, and Interventions for Children Ages 4 and older
Diagnosis Typical symptoms Behavioral interventions known to work (Evidence-informed; Manualized) *Descriptions provided below Trauma-related disorders Post-traumatic stress disorder --------------------------
More informationThis continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC.
This continuing education activity is co-sponsored by Indiana University School of Medicine and by CME Outfitters, LLC. Indiana University School of Medicine and CME Outfitters, LLC, gratefully acknowledge
More informationo DOSAGE AND ADMINISTRATION Dosage in Special Populations: The recommended initial dose is 0.5 mg BID in patients who are elderly
Some critics of Janssen, including plaintiff s lawyers, have stated it is improper for Risperdal to have been used to treat elderly dementia patients. As you consider that position, we suggest you consider
More informationTreating Mood and Anxiety Disorders in Children & Adolescents
Treating Mood and Anxiety Disorders in Children & Adolescents Daniel S. Pine, MD Section on Development & Affective Neuroscience Disclosures: Conflicts Sources of Research Support National Institute of
More informationIrritability and DSM-5 Disruptive Mood Dysregulation Disorder (DMDD): Correlates, predictors, and outcome in children
Irritability and DSM-5 Disruptive Mood Dysregulation Disorder (DMDD): Correlates, predictors, and outcome in children Ellen Leibenluft, M.D. Chief, Section on Bipolar Spectrum Disorders National Institute
More informationDisorders Mandate. Medical Coverage Policy Autism Spectrum EFFECTIVE DATE: 10/01/2013 POLICY LAST UPDATED: 08/05/2014
Medical Coverage Policy Autism Spectrum Disorders Mandate EFFECTIVE DATE: 10/01/2013 POLICY LAST UPDATED: 08/05/2014 OVERVIEW Applied behavioral analysis (ABA) is the process of systematically applying
More informationATYPICALS ANTIPSYCHOTIC MEDICATIONS
The atypical antipsychotics are a class of drugs that are used to treat a number of behavioral health disorders, including schizophrenia, other psychotic disorders, mood disorders, and behavioral agitation
More informationHandout 2 List of medications used to treat mental illness
Navigating Boundaries: Setting Sail With A Mentally Ill Client Handout 2 List of medications used to treat mental illness Information synthesized from www.drugs.com. Additional Information: CR following
More informationMedication Management of Depressive Disorders in Children and Adolescents. Satya Tata, M.D. Kansas University Medical Center
Medication Management of Depressive Disorders in Children and Adolescents Satya Tata, M.D. Kansas University Medical Center First Line Medications SSRIs Prozac (Fluoxetine): 5-605 mg Zoloft (Sertraline):
More informationUnder the Start Your Search Now box, you may search by author, title and key words.
VISTAS Online VISTAS Online is an innovative publication produced for the American Counseling Association by Dr. Garry R. Walz and Dr. Jeanne C. Bleuer of Counseling Outfitters, LLC. Its purpose is to
More informationOCD & Anxiety: Helen Blair Simpson, M.D., Ph.D.
OCD & Anxiety: Symptoms, Treatment, & How to Cope Helen Blair Simpson, M.D., Ph.D. Professor of Clinical Psychiatry, Columbia University Director of the Anxiety Disorders Clinic, New York State Psychiatric
More informationTHE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine
THE DEPRESSION RESEARCH CLINIC Department of Psychiatry and Behavioral Sciences Stanford University, School of Medicine Volume 1, Issue 1 August 2007 The Depression Research Clinic at Stanford University
More informationA Guide to Tourette Syndrome Medications by John T. Walkup M.D.
llllllllllllllll A TSA MEDICAL PUBLICATION A Guide to Tourette Syndrome Medications by John T. Walkup M.D. This publication is intended to provide information about Tourette Syndrome, its management and
More informationMedications for Huntington s Disease Vicki Wheelock, M.D.
Medications for Huntington s Disease Vicki Wheelock, M.D. Director, HDSA Center of Excellence at UC Davis June 4, 2013 Outline Introduction and disclaimers Medications for cognitive symptoms Medications
More informationMedication in Autism Spectrum Disorders What Works and What Doesn t
Medication in Autism Spectrum Disorders What Works and What Doesn t Dr Paramala Santosh, MBBS, MD, DipNB (Psych), FRCPsych, PhD Head, Centre for Interventional Paediatric Psychopharmacology (CIPP) Great
More informationA Parent Management Training Program for Parents of Very Young Children with a Developmental Disability
A Parent Management Training Program for Parents of Very Young Children with a Developmental Disability Marcia Huipe April 25 th, 2008 Description of Project The purpose of this project was to determine
More informationMoody Kids, Bipolar Disorder, and Medication Treatment Strategies. Learning Objectives. Mood Episodes. Irritability and Anger are Nonspecific Symptoms
Moody Kids, Bipolar Disorder, and Medication Treatment Strategies May 6, 2016 Dara Sakolsky, MD, PhD Associate Medical Director, STAR Clinic Assistant Professor of Psychiatry University of Pittsburgh Medical
More informationTreatment interventions for people with aggressive behaviour and intellectual disability
Chapter 4 Treatment interventions for people with aggressive behaviour and intellectual disability Peter Sturmey DEFINITION AND DIAGNOSIS OF AGGRESSION The term aggression is used widely and loosely to
More informationPervasive Developmental Disorders: Autism
CHAPTER 16 Pervasive Developmental Disorders: Autism Lisa A. Ruble, PhD, and Shannon Brown, PhD Every primary care physician can expect to treat an individual with autism. 1 Until recently autism was considered
More informationSelective serotonin re-uptake inhibitors in child and adolescent depression
Galantamine (Reminyl) Selective serotonin re-uptake inhibitors in child and adolescent depression Summary The Therapeutic Goods Administration has issued warnings about risks of using selective serotonin
More informationPsychotropic Medication Reference Chart
Psychotropic Medication Reference Chart Appendix 4.14 This chart is not an all-inclusive list of medications. If you have a question regarding the classification of a medication you may consult websites
More informationStep 4: Complex and severe depression in adults
Step 4: Complex and severe depression in adults A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive
More informationI. The Positive Symptoms...Page 2. The Negative Symptoms...Page 2. Primary Psychiatric Conditions...Page 2
SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Assessment & Treatment of Psychosis Developed March 1, 2003 Revised September 21,
More informationManagement of Children With Autism Spectrum Disorders
CLINICAL REPORT Management of Children With Autism Spectrum Disorders Guidance for the Clinician in Rendering Pediatric Care Scott M. Myers, MD, Chris Plauché Johnson, MD, MEd, the Council on Children
More informationBehavior and Developmental Disorders, Bipolar Disorder, and Schizophrenia Comparing safety and effectiveness
Use of Antipsychotic Medication in Children and Teens to Treat: Behavior and Developmental Disorders, Bipolar Disorder, and Schizophrenia Comparing safety and effectiveness Contents Our Recommendations.......................................
More informationApplied Behavior Analysis for Autism Spectrum Disorders
Applied Behavior Analysis for Autism Spectrum Disorders I. Policy University Health Alliance (UHA) will reimburse for Applied Behavioral Analysis (ABA), as required in relevant State of Hawaii mandates,
More informationTreating Children with Anxiety and Bipolar Disorder. Ellen Leibenluft, M.D.
Treating Children with Anxiety and Bipolar Disorder Ellen Leibenluft, M.D. Chief, Section on Bipolar Spectrum Disorders Emotion and Development Branch National Institute of Mental Health National Institutes
More informationValueOptions Autism Care Management Product. Bryan Davey, PhD, BCBA-D Christopher Dennis, MD, MBA, ValueOptions Chief Medical Officer
ValueOptions Autism Care Management Product Bryan Davey, PhD, BCBA-D Christopher Dennis, MD, MBA, ValueOptions Chief Medical Officer Autism Spectrum Disorders Background 2 Autism Spectrum Disorders within
More informationAppropriate Use of Psychotropic Drugs in Children and Adolescents: A Clinical Monograph
MAGELLAN HEALTH, INC. Appropriate Use of Psychotropic Drugs in Children and Adolescents: A Clinical Monograph Important Issues and Evidence-Based Treatments MagellanHealth.com Contents Introduction 2
More informationCLINICIAN INTERVIEW COMPLEXITIES OF BIPOLAR DISORDER. Interview with Charles B. Nemeroff, MD, PhD
COMPLEXITIES OF BIPOLAR DISORDER Interview with Charles B. Nemeroff, MD, PhD Dr Nemeroff is the Reunette W. Harris Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Emory
More informationAUTISM SPECTRUM DISORDERS
AUTISM SPECTRUM DISORDERS JAGWINDER SANDHU, MD CHILD, ADOLESCENT AND ADULT PSYCHIATRIST 194 N HARRISON STREET PRINCETON, NJ 08540 PH: 609 751 6607 Staff Psychiatrist Carrier clinic Belle Mead NJ What is
More informationRecognizing and Treating Depression in Children and Adolescents.
Recognizing and Treating Depression in Children and Adolescents. KAREN KANDO, MD Division of Child and Adolescent Psychiatry Center for Neuroscience and Behavioral Medicine Phoenix Children s Hospital
More informationThese guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes.
This is a new guideline. These guidelines are intended to support General Practitioners in the care of their patients with dementia both in the community and in care homes. It incorporates NICE clinical
More informationLeading European Psychiatrists, Janssen-Cilag and Scientific Fraud
Concerta for adults Leading European Psychiatrists, Janssen-Cilag and Scientific Fraud December 9, 2011 How could leading European psychiatrists claim that the ADHD drug Concerta was safe and worked fantastically
More informationObsessive Compulsive Disorder What you need to know to help your patients
Obsessive Compulsive Disorder What you need to know to help your patients By Renae M. Reinardy, PsyD, LP, and Jon E. Grant, MD Obsessive compulsive disorder (OCD) is a condition that affects millions of
More informationantidepressants depression in children Should be used to treat and adolescents?
Should antidepressants be used to treat depression in children and adolescents? Key advisor: Dr Sally Merry, Senior lecturer in child and adolescent psychiatry, Werry Centre for Child and Adolescent Mental
More informationThe following is a sample of psychotropic drug warnings that drug regulatory agencies
Chronology of International Drug Regulatory Agency Warnings about Psychotropic Drugs The following is a sample of psychotropic drug warnings that drug regulatory agencies around the world have issued.
More informationTreatment: Healing Actions, Healing Words
Treatment: Healing Actions, Healing Words 15 : Insight-Oriented Therapy Psychoanalysis (p.687) First use of a talking cure Developed by Sigmund Freud Identify unconscious motivations Free association Dream
More informationRegence. Section: Mental Health Last Reviewed Date: January 2013. Policy No: 18 Effective Date: March 1, 2013
Regence Medical Policy Manual Topic: Applied Behavior Analysis for the Treatment of Autism Spectrum Disorders Date of Origin: January 2012 Section: Mental Health Last Reviewed Date: January 2013 Policy
More informationTENNCARE MEDICAL NECESSITY GUIDELINES Procedure: Applied Behavioral Analysis Page 2 of 5
Procedure: Applied Behavioral Analysis Origin Date: 1/10/2006, Revised 01/27/ 2015 Approved by: Vaughn Frigon, M.D. Page 1 of 5 Applied Behavioral Analysis Medical Necessity Guidelines I. Description of
More informationDSM-5. Presented by CCESC School Psychologist Interns: Kayla Dodson, M.Ed. Ellen Doll, M.S. Rich Marsicano, Ph.D. Elaine Wahl, Ph.D.
DSM-5 Presented by CCESC School Psychologist Interns: Kayla Dodson, M.Ed. Ellen Doll, M.S. Rich Marsicano, Ph.D. Elaine Wahl, Ph.D. Introduction Lifespan approach to diagnosis Diagnoses occurring in children
More informationBest Practices in Children's Mental Health:
Best Practices in Children's Mental Health: A Series of Reports Summarizing the Empirical Research on Selected Topics Report #4 "Outcome Studies of Children and Adolescents with Autism" December 2002 Produced
More informationMOOD DISORDERS PART II BIPOLAR AFFECTIVE DISORDER (BAD) Todd Stull, M.D. James Sorrell, M.D.
MOOD DISORDERS PART II BIPOLAR AFFECTIVE DISORDER (BAD) Todd Stull, M.D. James Sorrell, M.D. BIPOLAR AFFECTIVE DISORDER (BAD) General Assessment is challenging Input important Change in level of functioning
More informationThis program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
This program is approved for 1.0 contact hour of continuing education (which includes 0.25 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 1012385. This program was planned
More informationTITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines
TITLE: Cannabinoids for the Treatment of Post-Traumatic Stress Disorder: A Review of the Clinical Effectiveness and Guidelines DATE: 01 December 2009 CONTEXT AND POLICY ISSUES: Post-traumatic stress disorder
More informationMelissa D. Carter, JD Barton Child Law & Policy Center Brent Wilson, MD Child Welfare Collaborative
Melissa D. Carter, JD Barton Child Law & Policy Center Brent Wilson, MD Child Welfare Collaborative Scope of the Problem Legal and Policy Considerations Social Work and Medical Practices Advocacy Opportunities
More informationHow To Ensure That Children With Angegea Are Treated Properly
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL SECOND-GENERATION ANTIPSYCHOTIC DRUG USE AMONG MEDICAID-ENROLLED CHILDREN: QUALITY-OF-CARE CONCERNS Daniel R. Levinson Inspector General
More informationDocumentation Guidelines for ADD/ADHD
Documentation Guidelines for ADD/ADHD Hope College Academic Success Center This document was developed following the best practice recommendations for disability documentation as outlined by the Association
More informationPSYCHOTROPIC MEDICATIONS: AN UPDATE FOR SCHOOL PSYCHOLOGISTS
, Vol. 50(6), 2013 View this article online at wileyonlinelibrary.com/journal/pits C 2013 Wiley Periodicals, Inc..21696 PSYCHOTROPIC MEDICATIONS: AN UPDATE FOR SCHOOL PSYCHOLOGISTS NANCY RAPPAPORT AND
More informationAutism Spectrum Disorders: Screening, Referrals, Treatment
Autism Spectrum Disorders: Screening, Referrals, Treatment Lauren Kenworthy, Ph.D. (lkenwort@childrensnational.org) Sinan Turnacioglu M.D. (sturnaci@childrensnational.org) June 2, 2014 Objectives What
More informationMental Health & Behavioral Disorders in Children
Family Education & Support Caregiver Program Session 3 Mental Health & Behavioral Disorders in Children Types of Behaviors & Symptoms to Watch For Externalizing Behaviors directed toward other people or
More informationSuicide in Bipolar Disorder. Julie Anderson, MD Oregon State Hospital Psychiatrist OHSU Assistant Professor September 25, 2012
Suicide in Bipolar Disorder Julie Anderson, MD Oregon State Hospital Psychiatrist OHSU Assistant Professor September 25, 2012 Disclosure Statement I have no significant financial relationships to disclose...
More informationLong Term Care Formulary HCD - 09. Anti-Dementia Drugs (e.g. donepezil, galantamine, rivastigmine, memantine)
1 of 8 USE OF CHOLINESTERASE (AChE) INHIBITORS The cholinesterase inhibitor anti-dementia drugs are indicated for the symptomatic treatment of patients with mild to moderate dementia of the Alzheimer s
More informationMOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION
MOH CLINICAL PRACTICE GUIDELINES 6/2011 DEPRESSION Executive summary of recommendations Details of recommendations can be found in the main text at the pages indicated. Clinical evaluation D The basic
More informationAntipsychotic drugs are the cornerstone of treatment
Article Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic T. Scott Stroup, M.D.,
More informationADHD Agents (Adult) Prior Authorization Criteria
ADHD Agents (Adult) Prior Authorization Criteria Brand Generic Dosage Form Adderall amphetamine/dextroamphetamine oral tablet a Adderall XR amphetamine/dextroamphetamine extended-release oral capsule Concerta
More informationAttention-deficit/hyperactivity disorder (ADHD)
5C WHAT WE KNOW ADHD and Coexisting Conditions: Depression Attention-deficit/hyperactivity disorder (ADHD) is a common neurobiological condition affecting 5-8 percent of school age children 1,2,3,4,5,6,7
More informationASD, ABA and Impact on Caregiver Burden. Erin Nolan & Fletcher Wood
ASD, ABA and Impact on Caregiver Burden Erin Nolan & Fletcher Wood Family Match ALEX, 6 Max, 6 Background Family Match Growing numbers of children identified with autism (suggested 1 in 50 by CDC). ABA
More informationTourette syndrome and co-morbidity
Tourette syndrome and co-morbidity Nanette M.M. Mol Debes, M.D., Ph.D. Tourette clinic, Herlev University Hospital, Denmark Outline of presentation Research project Herlev University Hospital Denmark Prevalence
More informationMental Health and Addictions, Practical Information for Supporting Students with Mental Health Challenges. May 2013
Mental Health and Addictions, Practical Information for Supporting Students with Mental Health Challenges May 2013 Parts of this presentation are adapted from the Mental health awareness workshop developed
More informationTREATMENT-RESISTANT DEPRESSION AND ANXIETY
University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine Definition of treatment resistance Failure to remit after 2
More information